CERTAIN PERSONAL INFORMATION IN THIS EXHIBIT, MARKED BY [*], HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K.

March 26, 2026

Eric Loumeau

[*]

Re: Terms of Separation

Dear Eric:

This letter confirms the agreement (“Agreement”) between you and AnaptysBio, Inc. (the “Company” or “Anaptys”) concerning the terms of your mutual separation and offers you the separation compensation below in exchange for a general release of claims and covenant not to sue. If you choose to enter into this Agreement, please sign below, on March 26, 2026.

Separation Date; Transition Services:

a.

Separation Date: Your last day of employment with the Company will be the date on which the Company completes the distribution to its stockholders of shares of common stock of First Tracks Biotherapeutics, Inc. (“TRAX”) (the “Separation Date”).

b.

…

CERTAIN PERSONAL INFORMATION IN THIS EXHIBIT, MARKED BY [*], HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K.

March 26, 2026

Dennis Mulroy

[*]

Re: Terms of Separation

Dear Dennis:

This letter confirms the agreement (“Agreement”) between you and AnaptysBio, Inc. (the “Company”) concerning the terms of your mutual separation and offers you the separation compensation below in exchange for a general release of claims and covenant not to sue. If you choose to enter into this Agreement, please sign below on March 26, 2026.

Separation Date; Transition Services:

a.

Separation Date: Your last day of employment with the Company will be the date on which the Company completes the distribution to its stockholders of shares of common stock of First Tracks Biotherapeutics, Inc. (“TRAX”) (the “Separation Date”).

b.

…

CERTAIN PERSONAL INFORMATION IN THIS EXHIBIT, MARKED BY [*], HAS BEEN REDACTED PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K.

CONSULTING AGREEMENT

This Consulting Agreement (“Agreement”) is entered into as of April 20, 2026, (the “Effective Date”), between AnaptysBio, Inc., a Delaware corporation having its principal place of business in San Diego, California (“Company” or “Anaptys”), and Daniel Faga, an individual whose address is [*] (“Consultant”, and collectively with the Company, the “Parties”).

WHEREAS, the Company will complete a distribution to its stockholders of shares of common stock of First Tracks Biotherapeutics, Inc. (“TRAX”), a wholly owned subsidiary of the Company (the “Transaction”), which is anticipated to be completed on April 20, 2026;

WHEREAS, TRAX is a newly formed public company; and

WHEREAS, Consultant has agreed to provide consulting services to the Company following the Transaction, on the terms and conditions set forth in this Agreement;

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE CMPETITIVE HARM TO ANABTYSBIO, INC. IF PUBLICLY DISCLOSED.

Exhibit 10.1

AMENDMENT NO. 6 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT

This Amendment No. 6 to the Collaboration and Exclusive License Agreement (this “Amendment”) is dated as of April 10, 2026 and effective as of January 30, 2026 (the “Amendment Date”), is entered into by and between (a) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (“AnaptysBio”), and (b) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”). Collectively, AnaptysBio and TESARO are referred to as the “Parties” and, individually, as a “Party.” All capitalize

…

SIDE LETTER AGREEMENT

May 7, 2026

This Side Letter Agreement (this “Side Letter Agreement”), dated as of May 7, 2026, is by and between CID Holdco, Inc. (the “Company”) and White Lion Capital, LLC (“White Lion”). The Company and White Lion are collectively referred to herein as the “Parties”.

Reference is made to that certain Note Purchase Agreement (the “Note Purchase Agreement”), dated April 17, 2026, by and between the Parties. Capitalized terms used but not defined herein shall have the definitions ascribed to them by the Note Purchase Agreement.

In consideration of the mutual agreements contained herein, the Parties hereby agree as follows:

1. Amendments to Note Purchase Agreement. White Lion and the Company acknowledge and agree to the following terms and conditions in addition to those set forth in the Note Purchase Agreement:

…

X4 Pharmaceuticals, Inc. SECOND AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN

(AS AMENDED AND RESTATED MAY 11, 2026)

1.    Purpose

The purpose of this Second Amended and Restated 2017 Equity Incentive Plan (the “Plan”) of X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (t) of the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Com

…

ADVISORY AGREEMENT

This Advisory Agreement (the “Agreement”) is made by and between TransAct Technologies Incorporated, a Delaware corporation with a mailing address of One Hamden Center, 2319 Whitney Avenue, Suite 3B, Hamden, CT 06518 (the “Company”) and Steven A. DeMartino (“you”, “Contractor” or “your”).

1.       The term of this Agreement (the "Term") will be effective as of July 1, 2026, and will continue until December 31, 2026, unless terminated by you or terminated by the Company for Cause as defined in your Employment Agreement..

…

SEPARATION AGREEMENT AND GENERAL RELEASE

This Separation Agreement and General Release (the “Agreement”) confirms the following understandings and agreements between TransAct Technologies Incorporated, a Delaware corporation with a mailing address of One Hamden Center, 2319 Whitney Avenue, Suite 3B, Hamden, CT 06518 (the “Company”) and Steven A. DeMartino (“Executive”) (the Company and Executive are collectively, the “Parties”).

RECITALS

…

July 15, 2025

VIA EMAIL ONLY

Dear Susan:

This letter sets forth our agreement (the "Letter Agreement") regarding advisory services to be provided

by you to the Board of Directors of Andersen Group Inc. ("AGI") and your eventual service as a director on the Board of AGI.

1.Effective as of July 16, 2025, you will act as an advisor ("Advisor") to the Board of Directors of AGI, a Delaware corporation until such time as you become a director ("Director") on the Board of AGI which shall occur by no later than July 1, 2026, unless either party provides the other with reasonable advance written notice of termination of your services as an Advisor or Director at any time.

2.Remuneration as follows:

…

FOURTH AMENDED AND RESTATED INVESTMENT ADVISORY

AND MANAGEMENT AGREEMENT

BETWEEN

ARES STRATEGIC INCOME FUND

AND

ARES CAPITAL MANAGEMENT LLC

This Fourth Amended and Restated Investment Advisory and Management Agreement (this “Agreement”), dated as of May 12, 2026 and effective as of June 6, 2026 (the “Effective Date”), is made by and between Ares Strategic Income Fund, a Delaware statutory trust (the “Fund”), and Ares Capital Management LLC, a Delaware limited liability company (the “Adviser”).

WHEREAS, the Fund is a closed-end management investment company that has elected to be treated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “Investment Company Act”);

WHEREAS, the Adviser is an investment adviser that has registered under the Investment Advisers Act of 1940, as amended (the “Advisers Act”);

…

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 6, 2026, between Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), and each investor identified on the signature pages hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”). Subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and/or Rule 506 promulgated thereunder, the Company desires to issue and sell to each Investor, and each Investor, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

THE PARTIES HEREBY AGREE AS FOLLOWS:

	1.	Purchase and Sale of the Securities.

	1.1.	Sale and Issuance of the Securities.

…

Exhibit 10.2

PROMISSORY NOTE

$100,000.00	May 7, 2026
	Miami, FL

FOR VALUE RECEIVED, the undersigned, Non-Invasive Monitoring Systems, Inc., a Florida corporation with its principal place of business at 4400 Biscayne Blvd., Miami, FL 33137 (“Maker”), promises to pay to the order of Jane Hsiao of 4400 Biscayne Blvd., 15th Floor Miami, FL 33137 (“Payee”), at such place as may be designated in writing by Payee, the principal sum of ONE HUNDRED THOUSAND AND 00/XX ($100,000.00) (this “Note”).

The principal amount of the loan evidenced hereby, together with any accrued and unpaid interest, and any and all unpaid costs, fees and expenses accrued, shall be due and payable on June 30, 2026 (the “Maturity Date”).

All amounts outstanding from time to time hereunder shall bear interest at the rate of eleven percent (11%) per annum until such amounts are paid.

…